Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsThe authors showed that either the oral liquid of Shuanghuanglian, the lyophilized powder of Shuanghuanglian for injection or their bioactive components dose-dependently inhibited SARS-CoV-2 3CLpro as well as the replication of SARS-CoV-2 in Vero E6 cells.
[Acta Pharmacologica Sinica]
6445212 {6445212:B5Y6MNEF} apa 50 1 152405 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-a68ac95a500d5be00d43055c0b2a6eaf%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22B5Y6MNEF%22%2C%22library%22%3A%7B%22id%22%3A6445212%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Su%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-31%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESu%2C%20H.%2C%20Yao%2C%20S.%2C%20Zhao%2C%20W.%2C%20Li%2C%20M.%2C%20Liu%2C%20J.%2C%20Shang%2C%20W.%2C%20Xie%2C%20H.%2C%20Ke%2C%20C.%2C%20Hu%2C%20H.%2C%20Gao%2C%20M.%2C%20Yu%2C%20K.%2C%20Liu%2C%20H.%2C%20Shen%2C%20J.%2C%20Tang%2C%20W.%2C%20Zhang%2C%20L.%2C%20Xiao%2C%20G.%2C%20Ni%2C%20L.%2C%20Wang%2C%20D.%2C%20Zuo%2C%20J.%2C%20%26%23x2026%3B%20Xu%2C%20Y.%20%282020%29.%20Anti-SARS-CoV-2%20activities%20in%20vitro%20of%20Shuanghuanglian%20preparations%20and%20bioactive%20ingredients.%20%3Ci%3EActa%20Pharmacologica%20Sinica%3C%5C%2Fi%3E%2C%201%26%23x2013%3B11.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41401-020-0483-6%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41401-020-0483-6%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D6445212%26amp%3Bitem_key%3DB5Y6MNEF%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Anti-SARS-CoV-2%20activities%20in%20vitro%20of%20Shuanghuanglian%20preparations%20and%20bioactive%20ingredients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hai-xia%22%2C%22lastName%22%3A%22Su%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sheng%22%2C%22lastName%22%3A%22Yao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wen-feng%22%2C%22lastName%22%3A%22Zhao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Min-jun%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jia%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei-juan%22%2C%22lastName%22%3A%22Shang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hang%22%2C%22lastName%22%3A%22Xie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chang-qiang%22%2C%22lastName%22%3A%22Ke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hang-chen%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mei-na%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kun-qian%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hong%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jing-shan%22%2C%22lastName%22%3A%22Shen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wei%22%2C%22lastName%22%3A%22Tang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lei-ke%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geng-fu%22%2C%22lastName%22%3A%22Xiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Li%22%2C%22lastName%22%3A%22Ni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dao-wen%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jian-ping%22%2C%22lastName%22%3A%22Zuo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hua-liang%22%2C%22lastName%22%3A%22Jiang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fang%22%2C%22lastName%22%3A%22Bai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yan%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yang%22%2C%22lastName%22%3A%22Ye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ye-chun%22%2C%22lastName%22%3A%22Xu%22%7D%5D%2C%22abstractNote%22%3A%22Human%20infection%20with%20severe%20acute%20respiratory%20syndrome%20coronavirus%202%20%28SARS-CoV-2%29%20causes%20coronavirus%20disease%202019%20%28COVID-19%29%20and%20there%20is%20no%20cure%20currently.%20The%203CL%20protease%20%283CLpro%29%20is%20a%20highly%20conserved%20protease%20which%20is%20indispensable%20for%20CoVs%20replication%2C%20and%20is%20a%20promising%20target%20for%20development%20of%20broad-spectrum%20antiviral%20drugs.%20In%20this%20study%20we%20investigated%20the%20anti-SARS-CoV-2%20potential%20of%20Shuanghuanglian%20preparation%2C%20a%20Chinese%20traditional%20patent%20medicine%20with%20a%20long%20history%20for%20treating%20respiratory%20tract%20infection%20in%20China.%20We%20showed%20that%20either%20the%20oral%20liquid%20of%20Shuanghuanglian%2C%20the%20lyophilized%20powder%20of%20Shuanghuanglian%20for%20injection%20or%20their%20bioactive%20components%20dose-dependently%20inhibited%20SARS-CoV-2%203CLpro%20as%20well%20as%20the%20replication%20of%20SARS-CoV-2%20in%20Vero%20E6%20cells.%20Baicalin%20and%20baicalein%2C%20two%20ingredients%20of%20Shuanghuanglian%2C%20were%20characterized%20as%20the%20first%20noncovalent%2C%20nonpeptidomimetic%20inhibitors%20of%20SARS-CoV-2%203CLpro%20and%20exhibited%20potent%20antiviral%20activities%20in%20a%20cell-based%20system.%20Remarkably%2C%20the%20binding%20mode%20of%20baicalein%20with%20SARS-CoV-2%203CLpro%20determined%20by%20X-ray%20protein%20crystallography%20was%20distinctly%20different%20from%20those%20of%20known%203CLpro%20inhibitors.%20Baicalein%20was%20productively%20ensconced%20in%20the%20core%20of%20the%20substrate-binding%20pocket%20by%20interacting%20with%20two%20catalytic%20residues%2C%20the%20crucial%20S1%5C%2FS2%20subsites%20and%20the%20oxyanion%20loop%2C%20acting%20as%20a%20%5Cu201cshield%5Cu201d%20in%20front%20of%20the%20catalytic%20dyad%20to%20effectively%20prevent%20substrate%20access%20to%20the%20catalytic%20dyad%20within%20the%20active%20site.%20Overall%2C%20this%20study%20provides%20an%20example%20for%20exploring%20the%20in%20vitro%20potency%20of%20Chinese%20traditional%20patent%20medicines%20and%20effectively%20identifying%20bioactive%20ingredients%20toward%20a%20specific%20target%2C%20and%20gains%20evidence%20supporting%20the%20in%20vivo%20studies%20of%20Shuanghuanglian%20oral%20liquid%20as%20well%20as%20two%20natural%20products%20for%20COVID-19%20treatment.%22%2C%22date%22%3A%222020-07-31%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41401-020-0483-6%22%2C%22ISSN%22%3A%221745-7254%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.nature.com%5C%2Farticles%5C%2Fs41401-020-0483-6%22%2C%22collections%22%3A%5B%5D%2C%22dateModified%22%3A%222020-07-31T16%3A23%3A32Z%22%7D%7D%5D%7D
Su, H., Yao, S., Zhao, W., Li, M., Liu, J., Shang, W., Xie, H., Ke, C., Hu, H., Gao, M., Yu, K., Liu, H., Shen, J., Tang, W., Zhang, L., Xiao, G., Ni, L., Wang, D., Zuo, J., … Xu, Y. (2020). Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients. Acta Pharmacologica Sinica, 1–11. https://doi.org/10.1038/s41401-020-0483-6 Cite
